Examkin

Soru

Zorluk: ZorInfectious Diseases

Match each patient's clinical scenario regarding malaria prevention or treatment with the most appropriate targeted pharmacotherapy.

  • A 28-year-old primigravida at 16 weeks gestation is evaluated in the clinic prior to a 2-week trip to a chloroquine-resistant malaria-endemic region in sub-Saharan Africa. She is asymptomatic and her pregnancy is uncomplicated.Mefloquine
  • A 34-year-old man presents with cyclic fevers. Blood smear reveals Plasmodium vivax. His G6PD activity is normal. He is initiated on blood schizonticidal therapy with chloroquine.Primaquine
  • A 42-year-old woman returning from West Africa is brought to the emergency department with high fever, confusion, and oliguria. Laboratory analysis reveals a Plasmodium falciparum parasitemia of 15%.Intravenous artesunate
  • A 25-year-old man recently returned from Kenya presents to the clinic with a fever of 39.0°C (102.2°F). He is alert and oriented with normal renal and hepatic function. Blood smear reveals Plasmodium falciparum with 1% parasitemia.Artemether-lumefantrine

Cevap

The correct matches require pairing the pregnant traveler with Mefloquine, the P. vivax patient with Primaquine, the severe P. falciparum patient with Intravenous artesunate, and the uncomplicated P. falciparum patient with Artemether-lumefantrine.
Malaria management is highly specific to the clinical context. Mefloquine is the safe and recommended chemoprophylaxis for pregnant women traveling to chloroquine-resistant areas. Primaquine specifically targets the dormant liver hypnozoites of Plasmodium vivax to prevent relapse. Severe Plasmodium falciparum malaria (indicated by high parasitemia, confusion, and organ failure) requires emergent intravenous artesunate. Uncomplicated Plasmodium falciparum can be safely managed with oral artemisinin-based combination therapies, such as artemether-lumefantrine.

Adım Adım Çözüm

1
Evaluate the clinical status and species of malaria for each patient.
Patients are categorized into: prophylaxis in pregnancy, P. vivax hypnozoite eradication, severe P. falciparum, and uncomplicated P. falciparum.
Malaria treatment and prophylaxis algorithms depend heavily on clinical severity, Plasmodium species, local resistance patterns, and patient-specific factors.
2
Determine the appropriate regimen for the pregnant traveler.
Mefloquine is selected.
Mefloquine is the only recommended chemoprophylaxis for chloroquine-resistant areas that is safe in all trimesters of pregnancy. Doxycycline is teratogenic, and atovaquone-proguanil lacks sufficient safety data.
3
Determine the appropriate regimen to eradicate P. vivax hypnozoites.
Primaquine is selected.
P. vivax and P. ovale have dormant liver stages (hypnozoites) that standard blood schizonticides do not kill. Primaquine (or tafenoquine) is required to prevent relapse, provided the patient has normal G6PD levels.
4
Determine the appropriate therapy for severe P. falciparum malaria.
Intravenous artesunate is selected.
Severe malaria (defined by parasitemia >5%, altered mental status, renal failure, or respiratory distress) requires emergent parenteral therapy with intravenous artesunate to rapidly clear the parasite burden.
5
Determine the appropriate therapy for uncomplicated P. falciparum malaria.
Artemether-lumefantrine is selected.
Uncomplicated falciparum malaria in a chloroquine-resistant region is best treated with an oral artemisinin-based combination therapy (ACT).

Anahtar Kavram

Pharmacotherapy for malaria depends on the severity of illness, Plasmodium species, local resistance patterns, and patient-specific contraindications such as pregnancy or G6PD deficiency.
Bu soruyu puanla

Konular

Infectious Diseases

Bu konudan daha fazla soru